Cita APA

Piulats, J. M., Watkins, C., Costa García, M., del Carpio, L., Piperno-Neumann, S., Rutkowski, P., . . . Nathan, P. (2024). Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: A propensity score-weighted analysis.

Citación estilo Chicago

Piulats, J. M., C. Watkins, M. Costa García, L. del Carpio, S. Piperno-Neumann, P. Rutkowski, Luis de la Cruz Merino, y P. Nathan. Overall Survival From Tebentafusp Versus Nivolumab Plus Ipilimumab in First-line Metastatic Uveal Melanoma: A Propensity Score-weighted Analysis. 2024.

Cita MLA

Piulats, J. M., et al. Overall Survival From Tebentafusp Versus Nivolumab Plus Ipilimumab in First-line Metastatic Uveal Melanoma: A Propensity Score-weighted Analysis. 2024.